Study of two drugs for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan and cetuximab, for people with colorectal cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to other parts of the body or cannot be removed with surgery.
- You have already tried certain standard chemotherapy drugs (fluoropyrimidine, oxaliplatin, irinotecan), and if your tumor has a specific marker (MSI-H), you have also tried immunotherapy.
- Your tumor must have a specific protein level called HER2-low, which will be checked with a test on a biopsy or archived tissue sample.
- Your cancer has grown or you could not tolerate your last treatment.
- You are 18 years or older and able to do daily activities with little or no help (ECOG 0 or 1).
- Your organs (blood, kidneys, liver, heart) are functioning well enough, as shown by blood tests and an echocardiogram.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (trastuzumab deruxtecan, capecitabine, and bevacizumab) as the first treatment for people with HER2-positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
This trial tests a combination of two targeted drugs (against HER2) plus a chemotherapy drug called irinotecan for people with HER2-positive colorectal cancer that has spread and has not responded to standard treatments. The goal is to see if this combo can shrink or control the cancer better than current options.
This trial tests a new drug combination for people with advanced colorectal cancer that has a specific protein called HER2. The treatment includes a targeted drug (trastuzumab rezetecan) plus chemotherapy and another targeted drug (bevacizumab) to see if it can shrink tumors and help patients live longer.
This trial tests a drug called trastuzumab deruxtecan for people with advanced HER2-positive cancer of the esophagus, stomach, or gastroesophageal junction who haven't had prior systemic treatment for metastatic disease. The drug may help shrink tumors by targeting the HER2 protein and delivering chemotherapy directly to cancer cells.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.